Alex Gorsky to be Johnson & Johnson’s new CEO After Weldon

Alex Gorsky

Alex Gorsky

Johnson & Johnson has picked up a new CEO, to succeed Bill Weldon after his retirement in April this year. The healthcare giant J&J said its decade-old Chief Executive Officer William Weldon will step down from his post in April. To succeed him is the vice chairman Alex Gorsky, as the ninth chief executive officer of the 126 year-old company, while Weldon, aged 63, remains the chairman of the board.

Bill Weldon, who has served as CEO of Johnson & Johnson since 2002 and will remain on the company’s board of directors as chairman, said in a statement given to a business magazine that the selection process for his successor was thorough.

Weldon said, “This succession decision involved a rigorous, thorough and formal multi-year process, which included consideration of two superbly qualified internal candidates, as well as outside candidates. The future of J& J is in very capable hands.”

Several manufacturing magazines report that Gorsky, aged 51, is currently vice chairman of the company’s executive committee with responsibility for the Medical Devices & Diagnostics Group, Global Supply Chain, Health Care Compliance & Privacy and Government Affairs & Policy.

Gorksy’s appointment is effective April 26, 2012, the date of the healthcare giant J&J’s annual meeting of shareholders. He was also nominated for election to the board of directors at the annual meeting.

Weldon and the product recalls

Most likely, the news agencies must be focusing the stories of the announcement of the new CEO on the product recalls that have dogged the company for the past few years. But that seems a bit unfair, for Bill Weldon deserves credit for a lot of good management over his decade-plus near the top of one of the world’s biggest health care companies, and the consumer products debacle shouldn’t even rank among his worst foul-ups.

Over Weldon’s ten-year reign, J&J experienced its shares outperforming Pfizer, Merck, GlaxoSmithKline, and even Abbott Laboratories. The healthcare giant J&J also launched more drugs than its rivals – 11 during his term as chief executive and three more during his time as head of the pharmaceuticals business, between 1998 and 2002.

Gorsky’s time spend in J&J

Alex Gorsky first joined Johnson & Johnson as a sales representative for Janssen Pharmaceutica. Gorksy had advanced his way to become the president of Janssen by 2001.  In 2003, Alex Gorsky was promoted to oversee Johnson & Johnson’s pharmaceutical business in Europe, the Middle East and Africa. Thereafter he left J&J in 2004 and returned back after four years as head of pharmaceuticals in North America at Novartis. Gorsky was appointed as worldwide chairman of the surgical care group as well as the company’s executive committee, in 2009.

Erik Gordon, a business professor at the University of Michigan, in Ann Arbor said, “Gorsky is a conservative choice and the strongest internal candidate. That’s a big deal at a company that always taps an insider as its next CEO, even if what they need is someone from outside the team that led the company into so much trouble.”

 

Aubrey Chang
Aubrey Chang, Associate Editor Industry Leaders Magazine (www.industryleadersmagazine.com)

Recent Posts

iPhone 13 and iPhone 13 Pro: Specifications, Release Date, Features and much more

iPhone 13 and iPhone 13 Pro: Specifications, Release Date, Features and much more

Apple iPhone 13 Pro and iPhone 13 Pro Max can be a hit with its ever new technology A15 Bionic chip and other cool profound features.
11 hours ago
Total signs $27 billion energy deal to fund 1-gigawatt solar power plant

Total signs $27 billion energy deal to fund 1-gigawatt solar power plant

The French oil major, Total, has signed a $27 billion deal to fund a 1-gigawatt solar power plant, and boost oil and gas production in the Middle-East region.
12 hours ago
PMI seals $1.51 billion takeover of British inhalation specialist Vectura

PMI seals $1.51 billion takeover of British inhalation specialist Vectura

Philip Morris International (PMI) acquires a 22.6% stake in British inhalation specialist Vecutra closing in on the controversial $1.51 billion takeover.
1 day ago
Apple co-founder Steve Wozniak joins the space race

Apple co-founder Steve Wozniak joins the space race

Wozniak, popularly known as “Woz”, is setting up a private space company with Ripcord co-founder Alex Fielding. In a tweet, Wozniak shared a promotional video for the company c
2 days ago
Auto chip shortage affects its production; factory closures rise

Auto chip shortage affects its production; factory closures rise

Automakers like Peugot, Ford, and Toyota are on the run to regain high-margins from the auto chip making since the pandemic and weather disasters have taken over.
2 days ago
Boeing bullish on growth in Asia-Pacific region

Boeing bullish on growth in Asia-Pacific region

Boeing, the US manufacturer projects that its global fleet of airline planes will surpass 49,000 by 2040.
3 days ago